Skip to content
ClinCalc Pro
Menu
Synthetic prostaglandin E1 analogue

Gemeprost

Brand names: Cervagem

A prostaglandin E1 analogue administered as a vaginal pessary, used for cervical ripening and medical termination of pregnancy and in the management of intrauterine fetal death.

Dosing — no UK product information found

We found no UK product information (SmPC) for this medicine or presentation on the eMC or MHRA Products (checked October 2026). It may be unlicensed in the UK, imported, a medical device, or no longer marketed. ClinCalc Pro shows only doses it can trace to official product information, so none is shown — follow your specialist service or local guideline.

Clinical monograph

How it works

It stimulates uterine contractions and softens and dilates the cervix through prostaglandin receptor activation.

Prescribing in practice

  • It can cause strong uterine contractions with a risk of uterine rupture, severe bleeding and cardiovascular effects, so use under close clinical supervision.
  • Caution in cardiovascular disease and in women with risk factors for uterine rupture; pessaries require appropriate cold-chain storage.
  • Commonly causes uterine pain, vaginal bleeding, nausea, vomiting and diarrhoea.

Monitoring

Monitor uterine activity, vaginal bleeding, pain and cardiovascular observations during treatment.

Counselling the patient

  • Cramping uterine pain and vaginal bleeding are expected during treatment.
  • Nausea, vomiting or diarrhoea may occur.
  • Report heavy bleeding, severe pain or feeling faint to staff immediately.

Evidence & guidelines

Prostaglandin analogues are recommended within NICE abortion care guidance for medical termination of pregnancy.

Reference: RCOG guidance; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.